Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Utah
Clinical trial register · United States · industry-sponsored

Clinical Trials in Utah, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals13 Eli Lilly and Company9 GlaxoSmithKline6 Sanofi5 Pfizer5
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Utah

300 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
NCT03244072Endophthalmitis
DrugMoxifloxacin
Jason Ahee, M.D.
Phase 2/3
60,000
Utah
2027-06-01
Not yet open
Essential Oil-Based Product System for Digestive Support
NCT07653815Healthy
dōTERRA International
Not applicable
40
Utah
2026-11
Not yet open
Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy
NCT07743541Uterine Endometrial Cancer
Gilead Sciences
Phase 1/2
100
California, New Jersey, New York, Utah
2026-10
Recruiting
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07029945Geographic Atrophy
Biojiva LLC
Phase 1/2
152
Arizona, Mississippi, Nevada, Ohio, Texas, Utah, Washington
2026-09-29
Recruiting
UNITY DX Cornea Study
NCT07768735Tomography
Alcon Research
Observational
110
Utah
2026-09-24
Recruiting
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
California, Florida, New Jersey, Tennessee, Utah
2026-09-24
Not yet open
A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People
NCT07829406Healthy Volunteers
Novo Nordisk A/S
Phase 1
148
Utah
2026-09-17
Recruiting
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
NCT07780656Pulmonary Disease, Chronic Obstructive
DrugGSK5784283
GlaxoSmithKline
Phase 3
624
Florida, South Dakota, Utah
2026-09-11
Not yet open
A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults
NCT07819097Adult, Healthy Participants
DrugRSVpreF
Pfizer
Phase 3
600
Connecticut, Ohio, Pennsylvania, Utah, Virginia
2026-09-09
By invitation
Evaluation of Male and Female External Catheters for Urine Output Monitoring in the ICU
NCT07744945Urine Output, ICU Patients
C. R. Bard
Observational
32
Utah
2026-09-02
Not yet open
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
NCT07808697SARS-CoV-2
DrugsMRNA-1283·Efluelda (TIV-HD) and Spikevax
ModernaTX, Inc.
Phase 2
300
California, Florida, Illinois, Michigan, Ohio, Texas, Utah, Virginia
2026-09-01
Recruiting
A Study of COVID-19 Vaccine(s) in Children and Adults
NCT07798648COVID-19 Vaccines
DrugComirnaty
BioNTech SE
Phase 3
700
Florida, Georgia, Hawaii, Kentucky, Ohio, Pennsylvania, Texas, Utah
2026-08-31
Recruiting
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants
NCT07765706Healthy Volunteers
Insmed Incorporated
Phase 1
116
Utah
2026-08-25
Not yet open
First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors
NCT07686068Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
Phase 1/2
260
Texas, Utah, Virginia
2026-08-18
Recruiting
Agreement of Two OCT Biometers: A Pilot Study
NCT07782619Anterior Segment of Eye, Axial Length, Biometrics Measurement
Alcon Research
Observational
50
Utah
2026-08-17
Recruiting
Accelerated Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder
NCT07463703PTSD - Post Traumatic Stress Disorder
Cognitive FX
Not applicable
15
Utah
2026-08-14
Recruiting
Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)
NCT07759362Flexible Hammertoe, Semi-flexible Hammertoe
Endo USA Inc., a Keenova Therapeutics Company
Phase 3
554
California, Florida, Texas, Utah
2026-08-11
Recruiting
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
NCT07746713Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
100
Florida, Michigan, Utah
2026-08-05
Recruiting
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07601425Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
DrugATV-1601
Atavistik Bio, Inc
Phase 1/2
100
Arizona, Georgia, Indiana, Massachusetts, Minnesota, Utah
2026-07-27
Active, closed
iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers
NCT07064564Opioid Use Disorder
DrugNaltrexone
Akyso Therapeutics, LLC
Phase 1
33
Utah
2026-07-25
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Colorado, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Utah
2026-07-24
Recruiting
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
NCT07730450COVID-19 Vaccines
DrugBNT162b2 Vaccine
BioNTech SE
Phase 4
200
California, Florida, Hawaii, North Carolina, Utah
2026-07-23
Recruiting
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
NCT07601074Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
DrugLopinavir / Ritonavir
Daré Bioscience, Inc.
Phase 2
118
Arizona, Arkansas, Utah, Washington
2026-07-17
Recruiting
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
NCT07533942Meningioma
DrugONC206
Jazz Pharmaceuticals
Phase 2
30
California, Louisiana, Massachusetts, New York, Utah
2026-07-16
Recruiting
A Study of LY4178256 in Healthy Participants
NCT07698210Healthy Volunteers
Eli Lilly and Company
Phase 1
88
California, Utah
2026-07-16
Not yet open
Phase 3 Bunionectomy Study
NCT07490496Postoperative Pain, Bunion
Cali Pharmaceuticals LLC
Phase 3
112
Utah
2026-07-01
Not yet open
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
NCT07609472High-Grade Glioma (WHO III-IV)
FluoGuide A/S
Phase 2
76
Florida, New Hampshire, Pennsylvania, Texas, Utah
2026-06-30
Recruiting
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
NCT07654972Obesity, Overweight
Eli Lilly and Company
Phase 1
108
Texas, Utah
2026-06-24
Recruiting
A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Women
NCT07669077Healthy
DrugNipocalimab
Janssen Research & Development, LLC
Phase 1
8
Utah
2026-06-23
Recruiting
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
NCT07602777Sarcoma
DrugsRis-Rez·G-Csf
GlaxoSmithKline
Phase 1/2
64
Utah
2026-06-22
Active, closed
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
NCT07724340Adults With Overweight/Obesity and Type 2 Diabetes
Antag Therapeutics
Phase 2
150
Arizona, California, Florida, Georgia, Utah
2026-06-19
Recruiting
ColoSeal™ ICD System Anastomotic Protection Pivotal Study
NCT07429110Rectal Cancer Surgery
Averto Medical, Inc.
Not applicable
250
Florida, Ohio, South Carolina, Tennessee, Utah
2026-06-19
Recruiting
A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years
NCT07632274Pain
HALEON
Phase 1
12
Utah
2026-06-19
Active, closed
Efficacy and Safety of Acute Topical and Aromatic Essential Oil-Based Products for Cognitive Support
NCT07623811Healthy
dōTERRA International
Not applicable
100
Utah
2026-06-10
Active, closed
Efficacy and Safety of an Essential Oil-Based Product System for Immune Support
NCT07482644Healthy
dōTERRA International
Not applicable
40
Utah
2026-06-10
Recruiting
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
NCT07697560Chemotherapy-induced Peripheral Neuropathy (CIPN)
AnHorn Medicines Co. Ltd.
Phase 1
32
Utah
2026-06-10
Recruiting
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
NCT07626281Inclisiran Formulation
DrugInclisiran
Novartis Pharmaceuticals
Phase 1
152
Kansas, Texas, Utah
2026-06-09
Recruiting
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
NCT07613294Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
252
California, Florida, Idaho, Massachusetts, Michigan, Nevada, Pennsylvania, Utah
2026-06-01
Recruiting
Clareon TruPlus Study
NCT07502456Aphakia, Astigmatism
Alcon Research
Not applicable
122
Arizona, Ohio, South Carolina, Texas, Utah
2026-05-26
Recruiting
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
NCT07599982Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
DreaMed Diabetes
Not applicable
102
Maryland, Michigan, New York, North Carolina, Texas, Utah
2026-05-25
Recruiting
A Phase 1, First-in-human Study of VX-433
NCT07584434Narcolepsy Type 1 (NT1)
DrugsBupropion·Midazolam
Vertex Pharmaceuticals Incorporated
Phase 1
118
Utah
2026-05-21
Recruiting
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
NCT07646613Migraine
Aspeya, Inc.
Phase 2
108
California, Florida, Nevada, Tennessee, Utah
2026-05-19
Active, closed
Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study
NCT07425587Sepsis, Septic Shock
Bluejay Diagnostics, Inc.
Observational
450
Florida, Massachusetts, North Carolina, Tennessee, Utah
2026-05-04
Recruiting
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
NCT07264959Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Observational
150
Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah
2026-04-15
Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006Alopecia Areata
DrugLY4005130
Eli Lilly and Company
Phase 2
60
California, Florida, Massachusetts, Michigan, New Hampshire, Texas, Utah
2026-04-14
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
NCT07544589Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Dispatch Biotherapeutics
Phase 1
66
California, Florida, Massachusetts, Ohio, Tennessee, Utah
2026-04-13
Recruiting
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1
40
California, Texas, Utah
2026-04-13
Recruiting
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT07304154Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
DrugsKITE-363·Fludarabine·Cyclophosphamide
Kite, A Gilead Company
Phase 1
52
California, New York, Utah, Washington
2026-04-10
Recruiting
A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation
NCT07523750Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
566
Arkansas, California, Florida, New York, North Carolina, Texas, Utah
2026-04-02
Recruiting
A Study of LY4515100 in Participants With Pain Following Third Molar Removal
NCT07511816Acute Pain, Molar, Molar, Third, Surgery, Oral
DrugLY4515100
Eli Lilly and Company
Phase 2
212
Utah
2026-04-01
Not yet open
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults
NCT07447843Obesity & Overweight
Nature's Sunshine Products, Inc.
Not applicable
80
Utah
2026-04
By invitation
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
NCT07338968Choroidal Melanoma, Indeterminate Lesions
Aura Biosciences
Observational
100
California, Michigan, Minnesota, Oklahoma, South Carolina, Tennessee, Texas, Utah
2026-03-27
By invitation
Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
NCT07286201Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Polyganics BV
Not applicable
110
Colorado, Georgia, Illinois, Louisiana, Maryland, South Carolina, Texas, Utah
2026-03-19
Recruiting
Study in Advanced Solid Tumor Patients
NCT07300943Advanced Solid Tumor
Callio Therapeutics
Phase 1/2
306
Massachusetts, Tennessee, Texas, Utah
2026-03-19
Recruiting
Long-Term Outcomes of Teplizumab in Routine Clinical Care
NCT07360080Type 1 Diabetes
DrugTeplizumab
Sanofi
Observational
1,000
Georgia, New York, Utah
2026-03-19
Recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT07540572ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
DrugFulvestrant
IDEAYA Biosciences
Phase 1
160
Florida, New Jersey, New York, Texas, Utah, Virginia
2026-03-17
Recruiting
Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy
NCT07574385Hallux Valgus, Bunionectomy
DrugBupivacaine
Rebel Medicine Inc
Phase 2
60
Utah
2026-03-10
Active, closed
Essential Oil Inhalation and Acute Stress Response in Healthy Adults
NCT07473544Psychological Stress
dōTERRA International
Not applicable
200
Utah
2026-03-10
By invitation
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
NCT07660640Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
DrugVOY-101
Perceive Biotherapeutics, Inc.
Observational
88
Massachusetts, Texas, Utah
2026-03-03
Recruiting
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
NCT07453602Atopic Dermatitis (AD), Eczema
Arcutis Biotherapeutics, Inc.
Phase 1
125
Florida, Indiana, New Jersey, Texas, Utah
2026-03-02
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
Colorado, Florida, Michigan, New York, Tennessee, Texas, Utah, Virginia
2026-02-24
Recruiting
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
NCT07356323Arthroplasty Replacement, Knee, Arthroplasty Total Hip Replacement
Solventum US LLC
Not applicable
179
Indiana, Utah
2026-02-19
Recruiting
SUMMIT RISE Study of Acute Ischemic Stroke Patients
NCT07436156Acute Ischemic Stroke
Route 92 Medical, Inc.
Phase 4
500
Utah
2026-02-12
Recruiting
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
NCT07332455Neoplasms, Prostate
GlaxoSmithKline
Phase 1/2
54
California, Michigan, Pennsylvania, Utah
2026-02-10
Recruiting
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
NCT07232602Bladder Cancer
DrugsMK-3120·Enfortumab Vedotin·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
55
California, Illinois, New York, Ohio, Utah
2026-02-09
Not yet open
Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men
NCT07328542Hypogonadism, Male
DrugTestosterone Cypionate
Azurity Pharmaceuticals
Phase 4
144
Alabama, Florida, New York, Texas, Utah
2026-02
Recruiting
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
NCT07276373Neoplasms
DrugNivolumab
Corcept Therapeutics
Phase 1/2
50
California, Illinois, Michigan, Texas, Utah
2026-01-16
Active, closed
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
NCT07298330Chronic Hepatitis D Infection
DrugBulevirtide
Mirum Pharmaceuticals, Inc.
Phase 3
80
California, Colorado, Nevada, Ohio, Texas, Utah
2026-01-14
Recruiting
First-in-human Study of 7MW4911 in GI Cancer
NCT07216560GI Cancers
Drug7MW4911
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
200
Florida, Massachusetts, New York, Utah, Washington
2026-01-13
Recruiting
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT07190300Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
DrugsTulmimetostat·Prednisone/Prednisolone·Abiraterone·Darolutamide
Novartis Pharmaceuticals
Phase 1/2
181
Alabama, Iowa, Kansas, North Carolina, South Carolina, Utah
2026-01-13
Recruiting
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
NCT07229911Healthy Volunteers, Primary Sclerosing Cholangitis
Takeda
Phase 1
134
Utah
2026-01-07
Recruiting
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
NCT07282587Advanced Pheochromocytoma and Paraganglioma, PCPG
DrugONC206
Jazz Pharmaceuticals
Phase 2
90
California, Colorado, Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah
2026-01-02
Active, closed
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
NCT07109414Platinum-resistant Ovarian Cancer
DrugPrilukae
Novita Pharmaceuticals, Inc.
Phase 2/3
380
Arizona, Louisiana, New Mexico, Pennsylvania, Utah, Wisconsin
2025-12-29
Recruiting
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
DrugsEnlituo·Zirabev·Erbitux·Avastin
Pfizer
Phase 1
260
California, Michigan, New York, Texas, Utah
2025-12-23
Recruiting
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
NCT07266428Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2
170
Connecticut, Massachusetts, Michigan, Texas, Utah
2025-12-17
Recruiting
Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia
NCT07226648Fibromyalgia
SPIRE Therapeutics Inc.
Not applicable
180
Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah, West Virginia
2025-12-11
Recruiting
PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
NCT06602271Postoperative Pain, Acute
DrugPF614
Ensysce Biosciences
Phase 3
320
Georgia, Texas, Utah
2025-12-09
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
California, Texas, Utah
2025-12-05
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
DrugsCalderasib·Cetuximab
Merck Sharp & Dohme LLC
Phase 2
150
Maryland, Michigan, Nevada, New Jersey, Utah, Virginia
2025-12-04
Recruiting
A Phase 2 Study of CRD-4730 in CPVT
NCT06658899Catecholaminergic Polymorphic Ventricular Tachycardia
DrugCRD-4730
Cardurion Pharmaceuticals, Inc.
Phase 2
12
California, North Carolina, Texas, Utah, Wisconsin
2025-12-01
Recruiting
Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes
NCT07222787Radiculopathy Lumbar, Degenerative Lumbar Disc Disease
Providence Medical Technology, Inc.
Not applicable
250
Arizona, California, Illinois, New York, North Carolina, Ohio, Texas, Utah
2025-12-01
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
NCT06994845Primary Immunoglobulin A Nephropathy (IgAN)
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
31
California, Colorado, Florida, Pennsylvania, Utah
2025-11-27
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
NCT07278336Ovarian Cancer
DrugsBevacizumab·Carboplatin
AbbVie
Phase 1
285
California, Colorado, Illinois, Nebraska, Texas, Utah, Virginia
2025-11-27
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
DrugsCetuximab·Nab-paclitaxel·Gemcitabine·Pembrolizumab
Bristol-Myers Squibb
Phase 1/2
252
Maryland, Texas, Utah, Virginia
2025-11-25
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
Recruiting
A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population
NCT07006831Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function
Devyser Inc.
Observational
400
California, Georgia, Maryland, Massachusetts, Utah
2025-11-14
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Arizona, California, Florida, Maryland, Nevada, Pennsylvania, Texas, Utah
2025-11-10
Recruiting
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
NCT07203001Still´s Disease
DrugArumakimig
Novartis Pharmaceuticals
Phase 2
30
Ohio, Oregon, Utah
2025-11-03
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067Atrial Fibrillation
Novartis Pharmaceuticals
Phase 2
165
Mississippi, New Jersey, New York, North Carolina, Utah, Washington
2025-10-28
Recruiting
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
NCT07007962Immune Thrombocytopenia
DrugRilzabrutinib
Sanofi
Phase 3
60
California, Louisiana, Massachusetts, Michigan, Minnesota, New York, Oregon, Utah
2025-10-24
Recruiting
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
NCT06971731Phenylketonuria
DrugRepinatrabit
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
120
California, Florida, Illinois, Oregon, Pennsylvania, Tennessee, Texas, Utah
2025-10-20
Recruiting
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
NCT07215559Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsMacupatide·Eloralintide
Eli Lilly and Company
Phase 2
200
Arizona, Florida, Georgia, Nevada, New Jersey, Ohio, Texas, Utah
2025-10-16
Recruiting
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
NCT07160725Solid Tumours
DrugPumitamig
Bristol-Myers Squibb
Phase 1/2
540
California, Pennsylvania, South Dakota, Texas, Utah, Washington
2025-10-15
Recruiting
A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients
NCT07219771Knee Osteoarthritis
Doron Therapeutics Inc.
Phase 3
260
Alabama, California, Florida, Illinois, Pennsylvania, South Carolina, Utah
2025-10-14
Active, closed
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
NCT07161635Aphakia, Presbyopia
Alcon Research
Not applicable
110
California, Missouri, South Carolina, Texas, Utah
2025-10-14
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT07041099Sjögren, Sjogren Disease, Sjogren's Syndrome
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
36
Florida, New York, Tennessee, Texas, Utah
2025-10-01
Recruiting
EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures
NCT07020520Ureteral Stricture
Urotronic Inc.
Not applicable
60
California, Florida, Indiana, New York, Texas, Utah
2025-10-01
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
California, Colorado, Florida, Illinois, New York, North Carolina, Utah
2025-09-29
Recruiting
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
NCT07161544Stargardt Disease
AAVantgarde Bio Srl
Phase 1/2
75
Arizona, California, Florida, Minnesota, Texas, Utah
2025-09-29
Recruiting
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
NCT07136779Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
Phase 1/2
310
Michigan, Texas, Utah, Virginia
2025-09-23
Recruiting
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
NCT07207707Solid Tumor Malignancies
Kumquat Biosciences Inc.
Phase 1
78
California, Colorado, Florida, Michigan, Ohio, Texas, Utah, Virginia
2025-09-16
Recruiting
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
NCT07190469Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
ProteinQure Inc.
Phase 1
80
Texas, Utah
2025-09-16
By invitation
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
NCT07480343Open-angle Glaucoma (OAG)
Iantrek, Inc.
Observational
250
California, Florida, Georgia, Maryland, Nevada, Pennsylvania, Tennessee, Utah
2025-09-15
Recruiting
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
NCT07060716Kidney Transplant Rejection, Cell-free DNA
Insight Molecular Diagnostics
Observational
125
California, Florida, Ohio, Pennsylvania, Tennessee, Texas, Utah
2025-09-08
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
MBrace Therapeutics
Phase 1/2
150
California, Michigan, New Jersey, Texas, Utah, Virginia
2025-09-03
Recruiting
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
ALX Oncology Inc.
Phase 1
170
California, Florida, Michigan, New Jersey, Ohio, Oregon, Texas, Utah
2025-08-18
Recruiting
A Long-Term Study of JNT-517 in Participants With Phenylketonuria
NCT06628128Phenylketonuria (PKU)
DrugRepinatrabit
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
240
Florida, Oregon, Pennsylvania, Texas, Utah
2025-08-11
Recruiting
Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT
NCT05337241Refractory Ventricular Tachycardia
Thermedical, Inc.
Not applicable
130
Alabama, Pennsylvania, South Carolina, Tennessee, Utah
2025-08-09
Active, closed
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
NCT06876363X-Linked Chronic Granulomatous Disease
Ensoma
Phase 1/2
15
California, Florida, Massachusetts, Minnesota, New York, North Carolina, Utah
2025-08-05
Recruiting
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
NCT06607458Refractory Metastatic Colorectal Cancer
DrugsMelphalan·Trifluridine/Tipiracil·Bevacizumab
Delcath Systems Inc.
Phase 2
90
California, Florida, Kansas, Louisiana, Utah
2025-08-05
Recruiting
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
NCT07093580Healthy Participants
Shionogi
Phase 1
98
Kansas, Utah
2025-07-29
Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
NCT06328608Fabry Disease
Chiesi Farmaceutici S.p.A.
Phase 2/3
22
Arizona, Georgia, Iowa, Ohio, Utah, Virginia
2025-07-29
Recruiting
A Study of LY4088044 in Healthy Participants
NCT07090785Healthy
Eli Lilly and Company
Phase 1
104
California, Kansas, Texas, Utah
2025-07-24
Recruiting
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
NCT06961747Healthy Participants
DrugZilucoplan
UCB Biopharma SRL
Phase 1
15
Texas, Utah
2025-07-09
Active, closed
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
NCT06736990Idiopathic Pulmonary Fibrosis
Calluna Pharma AS
Phase 2
150
California, Colorado, Florida, Kansas, North Carolina, Ohio, Pennsylvania, Utah
2025-06-20
Recruiting
AERA Pediatrics Registry
NCT07071298Dysfunction of Eustachian Tube
Integra LifeSciences Corporation
Observational
300
California, Massachusetts, Michigan, Minnesota, Ohio, Pennsylvania, Texas, Utah
2025-06-17
Active, closed
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
NCT07003984Chikungunya Virus
Bavarian Nordic
Phase 3
720
California, District of Columbia, Florida, Nebraska, Ohio, Texas, Utah
2025-06-05
Recruiting
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
NCT06973564Advanced Solid Tumors
DrugJAB-23E73
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
294
Minnesota, Missouri, Ohio, Utah
2025-05-29
Active, closed
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373VEXAS, VEXAS Syndrome
DrugPacritinib
Swedish Orphan Biovitrum
Phase 2
156
Arizona, Massachusetts, Minnesota, New York, Ohio, Texas, Utah, Washington
2025-05-28
Recruiting
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
NCT06395285ROSAH
DrugDF-003
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Phase 1
12
Maryland, North Carolina, Utah
2025-05-27
Recruiting
A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition
NCT06581146X-Linked Myotubular Myopathy
Astellas Gene Therapies
Observational
50
California, Illinois, Massachusetts, Ohio, Pennsylvania, Utah
2025-05-19
Active, closed
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
NCT06907875Facioscapulohumeral Muscular Dystrophy
Epicrispr Biotechnologies, Inc.
Phase 1/2
12
California, Georgia, Maryland, Massachusetts, Utah
2025-05-08
Recruiting
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
NCT06850038Alagille Syndrome
Ipsen
Observational
30
California, Missouri, New York, Tennessee, Texas, Utah
2025-04-22
Recruiting
Fertilo In Vitro Research Study and Trial
NCT06858111In Vitro Maturation of Oocytes
Gameto, Inc.
Phase 3
500
California, Florida, Maryland, New York, North Carolina, Texas, Utah
2025-04-17
Active, closed
A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery
NCT06664788Hemostasis, Hemostatic Techniques
Ethicon, Inc.
Not applicable
108
California, Missouri, New Jersey, New York, Texas, Utah
2025-04-16
Recruiting
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT06843447Ovarian Cancer Recurrent
DrugsMK-2010·R-DXd·Zirabev·Mvasi
Merck Sharp & Dohme LLC
Phase 1/2
605
Connecticut, Kentucky, Louisiana, Massachusetts, New York, Oklahoma, Texas, Utah
2025-04-15
Recruiting
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
NCT06880549Advanced Solid Tumors
DrugPembrolizumab
ModernaTX, Inc.
Phase 1
42
California, Michigan, Texas, Utah
2025-03-25
Recruiting
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
NCT06801002Solid Tumor
Jabez Bioscience, Inc
Phase 1
25
Ohio, Utah
2025-03-17
Active, closed
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
NCT06833008Advanced Solid Tumor
Ipsen
Phase 1/2
42
Michigan, Tennessee, Texas, Utah, Virginia
2025-03-14
Active, closed
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338Viral Hepatitis
DrugsTobevibart·Elebsiran
Vir Biotechnology, Inc.
Phase 3
124
Arizona, California, Florida, Illinois, Maryland, New Jersey, New York, Utah
2025-03-12
Active, closed
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
NCT06736418Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Abdera Therapeutics Inc.
Phase 1
17
California, Florida, Maryland, Massachusetts, Minnesota, New York, Texas, Utah
2025-03-10
Active, closed
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
NCT06812988Type 1 Diabetes Mellitus
DrugBrivekimig
Sanofi
Phase 2
84
Georgia, Michigan, Texas, Utah
2025-02-28
Recruiting
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
NCT06597006Familial Hypercholesterolemia - Homozygous
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
9
California, District of Columbia, Missouri, Utah
2025-02-28
Recruiting
A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction
NCT06864884Acute Post Operative Pain, Third Molar Extraction Surgery
Arcato Laboratories, Inc.
Phase EARLY_PHASE1
30
Utah
2025-02-26
Recruiting
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
NCT07558668Moderate to Severe Atopic Dermatitis
Sitryx Therapeutics Ltd
Phase 1
149
Arkansas, California, Indiana, Ohio, Pennsylvania, Utah
2025-02-26
Recruiting
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
NCT06804824Advanced Solid Tumors
DrugsSotorasib·Trametinib
Vividion Therapeutics, Inc.
Phase 1
220
Michigan, Texas, Utah, Virginia
2025-02-25
Recruiting
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
MacroGenics
Phase 1
124
California, Massachusetts, Michigan, New York, Texas, Utah
2025-02-13
Active, closed
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
NCT06255028Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
DrugAldesleukin
Century Therapeutics, Inc.
Phase 1
6
California, Illinois, Texas, Utah, Washington
2025-02-06
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360SLE, SLE (Systemic Lupus)
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
24
Arizona, Florida, Iowa, New York, Tennessee, Texas, Utah
2025-01-21
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
NCT06667687Non-Hodgkin's Lymphoma
AbbVie
Phase 1
21
North Carolina, Oregon, Texas, Utah, Virginia
2025-01-16
Active, closed
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
NCT06715124Advanced Solid Tumors
Quanta Therapeutics
Phase 1
237
Colorado, Connecticut, Florida, Michigan, North Carolina, Tennessee, Texas, Utah
2025-01-14
Recruiting
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
NCT05960929Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
ONY
Phase 3
220
Arizona, California, Florida, Hawaii, New Jersey, New York, Tennessee, Utah
2025-01-01
Recruiting
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
NCT06710379Solid Tumors
Adcentrx Therapeutics
Phase 1
68
California, Michigan, Minnesota, Texas, Utah, Virginia
2024-12-30
Active, closed
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
NCT06653842Cutaneous Venous Malformations
DrugQTORIN rapamycin anhydrous
Palvella Therapeutics, Inc.
Phase 2
15
California, Colorado, Maryland, Minnesota, North Carolina, Ohio, Pennsylvania, Utah
2024-12-20
Recruiting
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
NCT06797336Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
240
California, Massachusetts, Michigan, Tennessee, Texas, Utah, Virginia
2024-12-19
Recruiting
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019Familial Hypercholesterolemia - Heterozygous
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
60
California, District of Columbia, Florida, New York, Utah, Virginia, West Virginia
2024-12-09
By invitation
A Study to Assess the Impact of a Nutritional Supplement on Wellbeing and Nutrient Absorption
NCT06749808Nutrition Status
Pharmanex
Not applicable
36
Utah
2024-12-01
Recruiting
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
NCT06678659Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas
Recursion Pharmaceuticals Inc.
Phase 1/2
170
California, Ohio, Tennessee, Utah
2024-11-21
Active, closed
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501Chronic Lymphocytic Leukemia
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
94
Florida, Georgia, Illinois, Maryland, Nebraska, Oregon, Texas, Utah
2024-11-14
Active, closed
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
NCT06654895Sepsis, Septic Shock
Bluejay Diagnostics, Inc.
Observational
700
Florida, Massachusetts, North Carolina, Tennessee, Utah
2024-11-12
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Georgia, Indiana, Ohio, Texas, Utah
2024-10-29
Active, closed
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
DrugMaralixibat
Mirum Pharmaceuticals, Inc.
Phase 3
90
California, Illinois, New York, Ohio, Texas, Utah
2024-10-14
Active, closed
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
NCT06471543Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Ikaria Bioscience Pty Ltd
Phase 1/2
108
Florida, Kentucky, Minnesota, Texas, Utah
2024-09-30
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
DrugBelimumab
GlaxoSmithKline
Phase 3
440
California, Florida, Missouri, New York, North Carolina, Pennsylvania, Texas, Utah
2024-09-11
Active, closed
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
NCT06260774Advanced Solid Tumor
TransCode Therapeutics
Phase 1/2
16
Texas, Utah, Virginia
2024-09-05
Active, closed
A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity
NCT06577766Obesity, Overweight
Novo Nordisk A/S
Phase 1
63
Kansas, Texas, Utah
2024-09-03
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795Solid Tumor, Adult
DualityBio Inc.
Phase 1/2
360
California, District of Columbia, Florida, Illinois, North Carolina, Pennsylvania, Tennessee, Utah
2024-09-03
Recruiting
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis
DrugsKYV-101·Fludarabine·Cyclophosphamide
Kyverna Therapeutics
Phase 2/3
66
California, Florida, Indiana, Missouri, Oregon, Pennsylvania, Texas, Utah
2024-08-28
Recruiting
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
NCT06562907Weight Management
DrugOmeprazole
Gilead Sciences
Phase 1
134
Florida, Texas, Utah
2024-08-28
Active, closed
Cancer Prevention for Young Rural Adults
NCT05618158Cancer
Klein Buendel, Inc.
Not applicable
1,796
Arizona, Colorado, New Mexico, Utah
2024-08-26
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
NCT06352359Advanced Solid Tumor
OncoC4, Inc.
Phase 1
72
California, Florida, Kentucky, Michigan, Pennsylvania, Texas, Utah
2024-08-23
Active, closed
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT05589896Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
Ossium Health, Inc.
Phase 1/2
12
California, Florida, Georgia, Michigan, Oregon, Tennessee, Texas, Utah
2024-08-16
Recruiting
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
NCT06469281Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsMvasi·Cemiplimab·Avastin·Bevacizumab
Regeneron Pharmaceuticals
Phase 1
90
Massachusetts, New Jersey, New York, Pennsylvania, Utah
2024-08-06
Recruiting
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06520345Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
520
California, Florida, Maryland, Nebraska, New York, Ohio, Oregon, Utah
2024-07-26
Active, closed
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
DrugsEnfortumab Vedotin·Sacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
38
California, Illinois, Indiana, Massachusetts, Missouri, New York, Ohio, Utah
2024-07-17
Active, closed
Safety and Efficacy of VDPHL01 in Males and Females With AGA
NCT06527365Androgenetic Alopecia, AGA, Male Pattern Baldness
DrugVDPHL01
Veradermics, Inc.
Phase 2
70
California, Indiana, New Jersey, Utah
2024-07-08
Recruiting
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
NCT06515470Breast Cancer
DrugFulvestrant
Biotheryx, Inc.
Phase 1
82
Minnesota, Nebraska, Texas, Utah, Virginia
2024-07-03
Recruiting
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
NCT05037968Degenerative Disc Disease, Spine Fusion, Leg Pain and/or Back Pain
Kuros Biosurgery AG
Not applicable
100
Connecticut, Illinois, Maryland, Michigan, North Carolina, Ohio, Utah, Virginia
2024-06-10
Recruiting
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
NCT06277219Advanced Solid Tumor
Latticon Antibody Therapeutics, Inc
Phase 1/2
150
Florida, Utah
2024-06-05
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
DrugTirzepatide
Eli Lilly and Company
Phase 3
300
California, Delaware, Idaho, Illinois, Indiana, New York, Texas, Utah
2024-06-03
Recruiting
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
NCT06343311B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma
Estrella Immunopharma, Inc.
Phase 1/2
27
California, Ohio, Oregon, Texas, Utah
2024-06-01
Active, closed
QTX3046 in Patients With KRAS G12D Mutations
NCT06428500Advanced Solid Tumor
Quanta Therapeutics
Phase 1
240
Michigan, North Carolina, Texas, Utah
2024-05-30
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin
Eli Lilly and Company
Phase 1
575
Arizona, California, Georgia, Michigan, New York, Ohio, Texas, Utah
2024-05-20
Active, closed
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
NCT05739942Newly Diagnosed and Recurrent Glioblastoma
DrugsGa-NeoB·Lu-NeoB
Novartis Pharmaceuticals
Phase 1
42
California, Colorado, Massachusetts, New York, Ohio, Utah
2024-05-15
Active, closed
Telerehabilitation Early After CNS Injury
NCT06069999Cerebral Stroke, Traumatic Brain Injury, Spinal Cord Injuries
TRCare, Inc.
Not applicable
60
California, Florida, Pennsylvania, Utah
2024-05-09
Recruiting
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT06249048Advanced Solid Tumor
DrugsKeytruda·Pembrolizumab
Strand Therapeutics Inc.
Phase 1/2
108
Arizona, California, Ohio, Pennsylvania, Texas, Utah
2024-05-03
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
DrugsMomelotinib·Pacritinib·Selinexor·Ruxolitinib
Karyopharm Therapeutics Inc
Phase 2
58
California, Maryland, New York, North Carolina, Ohio, Texas, Utah
2024-04-22
Recruiting
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
NCT06192576Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
Sanofi
Observational
10
Illinois, Ohio, Pennsylvania, Texas, Utah
2024-04-16
Recruiting
Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)
NCT06150716Pelizaeus-Merzbacher Disease
Ionis Pharmaceuticals, Inc.
Phase 1
24
Georgia, Pennsylvania, Utah
2024-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
California, Illinois, Minnesota, New York, Tennessee, Texas, Utah, Virginia
2024-04-10
Active, closed
Digital Bonding vs. Direct Bonding Study
NCT06266130Orthodontic Brackets
Solventum Orthodontics Corporation
Not applicable
138
California, Maine, New York, Utah, Wisconsin
2024-03-25
Recruiting
First Time in Human Study of Long Acting VH4524184 Formulations
NCT06310551HIV Infections
DrugsVH4524184·Phesgo
ViiV Healthcare
Phase 1
372
Kansas, Texas, Utah
2024-03-21
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Recruiting
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
NCT06271577Myocardial Infarction, Ischemia, Myocardial Ischemia, Heart Diseases
AliveCor
Not applicable
1,000
Minnesota, Utah
2024-03-12
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics
Phase 1
250
California, Michigan, New York, Oregon, Texas, Utah
2024-03-06
Recruiting
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
NCT06239116Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Rhythm Pharmaceuticals, Inc.
Phase 1/2
150
Alabama, Illinois, Massachusetts, Tennessee, Texas, Utah
2024-03-05
Active, closed
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
NCT06245915Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Arsenal Biosciences, Inc.
Phase 1/2
37
Arizona, California, Florida, Iowa, Massachusetts, New York, Texas, Utah
2024-02-26
Recruiting
SNV1521 in Participants With Advanced Solid Tumors
NCT06220864Advanced Solid Tumor
DrugsDB-1310·Abiraterone·Darolutamide
Synnovation Therapeutics, Inc.
Phase 1
400
Connecticut, Pennsylvania, Tennessee, Texas, Utah
2024-02-23
Active, closed
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
NCT06150820Pompe Disease (Late-onset)
Astellas Gene Therapies
Not applicable
119
Georgia, Kansas, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, Utah
2024-02-01
Recruiting
Accuro XV Ultrasound Imaging System for BoneEnhance and Fracture Detection Algorithms
NCT07853768Fracture Arm, Fracture Leg, Wrist Injury, Ankle Injury
Rivanna Medical, Inc.
Not applicable
25,000
California, Colorado, Connecticut, Texas, Utah, Virginia
2024-01-29
Active, closed
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743Cardiomyopathy, Hypertrophic
DrugMavacamten
Bristol-Myers Squibb
Phase 4
63
California, Georgia, Massachusetts, Ohio, Pennsylvania, Texas, Utah
2024-01-24
Active, closed
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT06120075Advanced Cancer
DrugDocetaxel
Arcus Biosciences, Inc.
Phase 1
91
Colorado, District of Columbia, Georgia, Michigan, New York, Pennsylvania, Texas, Utah
2024-01-19
Recruiting
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
NCT06173518Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
DrugAUTO1
Autolus Limited
Phase 1
30
Colorado, Illinois, Ohio, Pennsylvania, Texas, Utah
2023-11-16
Active, closed
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364Follicular Lymphoma (FL)
DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan
Regeneron Pharmaceuticals
Phase 3
733
Florida, Indiana, Kansas, Kentucky, Michigan, Texas, Utah, Wisconsin
2023-11-14
Recruiting
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
NCT05977751Contraception
Femasys Inc.
Not applicable
573
Arizona, California, Georgia, Idaho, New York, Ohio, Tennessee, Utah
2023-10-31
Recruiting
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
NCT06096974Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1
60
Ohio, Texas, Utah
2023-10-24
Active, closed
Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression
NCT06117501Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome
Axogen Corporation
Not applicable
20
Florida, Georgia, Indiana, New Mexico, Ohio, Pennsylvania, Utah
2023-10-19
Active, closed
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
NCT05987189Lung Cancer
Hummingbird Diagnostics
Observational
2,000
Georgia, Louisiana, Massachusetts, Michigan, New York, Pennsylvania, Texas, Utah
2023-10-18
Recruiting
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
NCT06357754Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
DrugsIdecabtagene vicleucel·Lisocabtagene maraleucel
Bristol-Myers Squibb
Observational
50
Oregon, Texas, Utah, Wisconsin
2023-10-06
Active, closed
Expanded Indications in the Pediatric BONEBRIDGE Population
NCT05615649Hearing Loss, Conductive, Hearing Loss, Mixed
Med-El Corporation
Not applicable
36
Colorado, Florida, New Jersey, North Carolina, Ohio, Utah
2023-10-03
Recruiting
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
NCT06043817Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament
Phase 1/2
345
California, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia
2023-09-26
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
California, Florida, Michigan, Ohio, Oklahoma, Tennessee, Texas, Utah
2023-09-26
Recruiting
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
NCT06193928Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
DrugsLivmarli·Maralixibat
Mirum Pharmaceuticals, Inc.
Observational
70
California, Colorado, Georgia, Missouri, Oregon, Pennsylvania, Utah
2023-09-21
By invitation
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
NCT06075537Mucopolysaccharidosis II
DrugTividenofusp alfa
Denali Therapeutics Inc.
Phase 2/3
99
California, Illinois, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Utah
2023-09-20
Active, closed
Azeliragon in MGMT Unmethylated Glioblastoma
NCT05986851Glioblastoma
Cantex Pharmaceuticals
Phase 2
30
Colorado, Florida, Michigan, Missouri, New York, Oklahoma, Utah, Washington
2023-09-12
Active, closed
Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT
NCT06021431Opioid Use Disorder
BehaVR LLC
Not applicable
128
California, Utah
2023-09-07
Recruiting
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
NCT05879367Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
DrugsDFMO·Eflornithine·Temodar·Temozolomide
Orbus Therapeutics, Inc.
Phase 1
66
Alabama, Michigan, New York, North Carolina, Ohio, Rhode Island, Texas, Utah
2023-07-24
Recruiting
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
NCT04808505Glycogen Storage Disease Type II Infantile Onset
DrugsCipaglucosidase alfa·Miglustat
Amicus Therapeutics
Phase 3
36
Florida, Georgia, North Carolina, Ohio, Pennsylvania, Utah
2023-07-18
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1/2
230
California, Michigan, New York, Ohio, Texas, Utah
2023-07-06
Recruiting
NIBP Validation Study
NCT05673408Critical Illness
Philips Clinical & Medical Affairs Global
Observational
189
Florida, North Carolina, Oregon, Texas, Utah
2023-06-23
Active, closed
Myopia Control Spectacle Lens Cessation Study
NCT05893979Myopia, Myopia Progression, Juvenile Myopia
SightGlass Vision, Inc.
Not applicable
90
California, Florida, Kansas, Missouri, New York, Tennessee, Texas, Utah
2023-06-23
Recruiting
Evaluation of Outcomes Following In-office Tympanostomy Using the Tula® System: a Prospective, Multi-center Registry
NCT05915078Otitis Media With Effusion, Acute Otitis Media, Otitis Media
Smith & Nephew, Inc.
Observational
200
Kentucky, New Jersey, New York, Utah
2023-06-15
Active, closed
NEUROMARK Registry Study
NCT05937308Chronic Rhinitis
Neurent Medical
Not applicable
150
Alabama, California, Florida, Kentucky, Texas, Utah, Virginia
2023-06-12
Active, closed
Study of LP-184 in Patients With Advanced Solid Tumors
NCT05933265Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer
DrugsOlaparib·Ipilimumab
Lantern Pharma Inc.
Phase 1/2
64
Arkansas, Indiana, Kentucky, Maryland, Pennsylvania, Texas, Utah
2023-06-09
Recruiting
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
NCT05930210Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound
Energenesis Biomedical Co., Ltd.
Phase 3
230
Florida, Georgia, Tennessee, Texas, Utah, Virginia
2023-05-30
Recruiting
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
NCT05765851Advanced Solid Tumor
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 1
108
Florida, Rhode Island, Utah, Virginia
2023-05-30
Recruiting
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
NCT05765812Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
DrugTemozolomide
Debiopharm International SA
Phase 1/2
116
Illinois, New York, Texas, Utah, Washington
2023-05-15
By invitation
G7 Freedom Constrained Vivacit-E Liners
NCT05587244Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures
Zimmer Biomet
Not applicable
202
Alabama, California, Florida, New Jersey, Ohio, Tennessee, Texas, Utah
2023-05-08
Active, closed
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
NCT05627557Childhood Idiopathic Nephrotic Syndrome
DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Methylprednisolone·Obinutuzumab
Hoffmann-La Roche
Phase 3
85
California, Florida, Georgia, New Jersey, North Carolina, Utah, Virginia
2023-03-29
Active, closed
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT05669482KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic
DrugsAvutometinib (VS-6766) and defactinib·Gemcitabine and nab-paclitaxel
Verastem, Inc.
Phase 1/2
40
California, Illinois, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Utah
2023-03-22
Recruiting
An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
NCT05757141Vanishing White Matter Disease
DrugFosigotifator
Calico Life Sciences LLC
Phase 1/2
50
Massachusetts, Pennsylvania, Utah
2023-03-13
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
DrugZugo-cel
CRISPR Therapeutics AG
Phase 1/2
120
Kansas, Missouri, Texas, Utah
2023-03-10
Active, closed
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
NCT05201066Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
DrugsSpartalizumab·Decitabine·Azacitidine·Venetoclax
Novartis Pharmaceuticals
Phase 2
33
Oregon, Utah
2023-02-28
Recruiting
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
NCT05682378Heterozygous or Homozygous Familial Hypercholesterolemia
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
195
Florida, New York, Ohio, Pennsylvania, Utah
2023-02-10
Recruiting
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
NCT06132503Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Lantern Pharma Inc.
Phase 1
110
Utah
2023-01-03
Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
102
Michigan, Missouri, Texas, Utah
2022-12-20
Recruiting
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801Hemophilia A, Hemophilia B
DrugMarstacimab
Pfizer
Phase 3
100
Utah
2022-12-09
Active, closed
Spectacle Lens Visual Acuity Assessments Study
NCT05650190Myopia, Myopia Progression, Juvenile Myopia
SightGlass Vision, Inc.
Not applicable
51
Florida, Kansas, Missouri, New York, Texas, Utah
2022-12-08
Recruiting
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
NCT05661461Tumor, Solid, Tumor, Advanced Solid Tumor
DrugNab-sirolimus
Aadi Bioscience, Inc.
Phase 1
28
Texas, Utah
2022-11-23
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide
Pfizer
Phase 3
1,060
Florida, Nebraska, Nevada, New Jersey, New York, Texas, Utah
2022-11-10
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
Alabama, California, Iowa, Michigan, Ohio, Texas, Utah, Virginia
2022-10-25
Active, closed
The MONARCH Case Series Study: SPRINT® Peripheral Nerve Stimulation for the Treatment of Head Pain
NCT05491915Cervicogenic Headache, Occipital Neuralgia
SPR Therapeutics, Inc.
Not applicable
50
California, Massachusetts, Minnesota, North Carolina, Texas, Utah
2022-10-24
Active, closed
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
NCT05535244Multiple Myeloma
DrugsCevostamab·Tocilizumab
Hoffmann-La Roche
Phase 1/2
90
Colorado, Florida, Maryland, Massachusetts, Minnesota, New York, Tennessee, Utah
2022-10-17
Recruiting
International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder
NCT05590715Autism Spectrum Disorder
Stalicla SA
Observational
1,500
Arizona, California, Florida, Illinois, Missouri, New Mexico, Texas, Utah
2022-10-13
Recruiting
M-Vizion™ Macroscopic Radiographic Study
NCT05721859Revision Hip Arthroplasty
Medacta USA
Observational
70
Illinois, Massachusetts, New Hampshire, North Carolina, Pennsylvania, Utah
2022-10-12
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT05537740Advanced Solid Tumors
DrugPembrolizumab
Bayer
Phase 1
129
Illinois, North Carolina, Texas, Utah
2022-10-11
Active, closed
Continued Access Study to Evaluate Performance of the Organ Recovery Systems _LifePort® Liver Transporter System, a Machine Perfusion System, for Liver Transplant (PILOT™_CA)
NCT05574361Liver Transplantation
Organ Recovery Systems, Inc.
Not applicable
385
Illinois, New Jersey, Ohio, Utah
2022-09-19
By invitation
Digital Care Programs for Female Pelvic Health
NCT05513417Pelvic Floor Disorders, Pelvic Pain, Pelvic Organ Prolapse, Pelvic Floor Muscle Weakness
Sword Health, SA
Observational
50,000
Utah
2022-08-29
Active, closed
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
NCT05524883Duchenne Muscular Dystrophy (DMD)
DrugZeleciment Rostudirsen
Dyne Therapeutics
Phase 1/2
86
California, Colorado, Georgia, Massachusetts, Ohio, Oregon, Pennsylvania, Utah
2022-08-12
Active, closed
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
NCT05468697Renal Cell Carcinoma
DrugsBelzutifan·Palbociclib
Merck Sharp & Dohme LLC
Phase 1/2
60
District of Columbia, Illinois, Massachusetts, Utah
2022-08-10
Active, closed
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
NCT05371080Herpes Zoster
GlaxoSmithKline
Phase 3
3,038
Arizona, Maryland, North Carolina, Pennsylvania, Tennessee, Texas, Utah
2022-08-10
Active, closed
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
NCT05180799NSCLC, Melanoma
DrugsPemetrexed·Nivolumab·Pembrolizumab
BioAtla, Inc.
Phase 1/2
320
California, Georgia, Indiana, New Jersey, New York, Ohio, Oregon, Utah
2022-08-03
Active, closed
A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study
NCT05613569Lumbosacral Radiculopathy
Kolon Life Science
Observational
5
Utah
2022-07-26
By invitation
Digital Care Programs for Musculoskeletal Health
NCT05417685Musculoskeletal Diseases
Sword Health, SA
Observational
300,000
Utah
2022-07-26
Active, closed
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613Mucopolysaccharidosis II
DrugsIdursulfase·Tividenofusp alfa
Denali Therapeutics Inc.
Phase 2/3
65
California, Illinois, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Utah
2022-07-21
Recruiting
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
NCT05329103Advanced Solid Tumor
Peel Therapeutics Inc
Phase 1
65
Arizona, California, North Carolina, Pennsylvania, Rhode Island, Texas, Utah, Virginia
2022-07-11
Active, closed
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
NCT05095727Glycogen Storage Disease
ModernaTX, Inc.
Phase 1/2
15
Connecticut, Massachusetts, North Carolina, Ohio, Pennsylvania, Texas, Utah
2022-06-01
Active, closed
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT05251714Advanced Solid Tumor, Breast Cancer
DrugsCFI-402257·Fulvestrant
Treadwell Therapeutics, Inc
Phase 1/2
44
Ohio, Texas, Utah, Virginia
2022-05-27
Recruiting
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
Newave Pharmaceutical Inc
Phase 1
100
Illinois, Massachusetts, North Carolina, Ohio, Texas, Utah
2022-05-08
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548Fabry Disease
DrugsAgalsidase beta·Replagal·Venglustat·Migalastat HCl
Sanofi
Phase 3
104
Alabama, California, Georgia, Illinois, New York, Texas, Utah, Virginia
2022-05-03
Recruiting
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
DrugsAvelumab·Aldesleukin·Nivolumab
Aulos Bioscience, Inc.
Phase 1/2
159
Florida, Michigan, Minnesota, Missouri, North Carolina, Tennessee, Texas, Utah
2022-04-04
Active, closed
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035Chronic Kidney Disease, Proteinuria
DrugFinerenone
Bayer
Phase 3
219
California, Florida, Maryland, Missouri, Ohio, Oregon, Utah, Washington
2022-03-28
Active, closed
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051Neoplasms
DrugsRemzistotug·GSK5764227·Nelistotug·Belrestotug
GlaxoSmithKline
Phase 1
152
California, North Carolina, Oklahoma, Pennsylvania, Texas, Utah
2022-03-22
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
DrugsMosunetuzumab·Venclyxto·Venclexta·Tocilizumab
Hoffmann-La Roche
Phase 1
332
Minnesota, New York, Ohio, Texas, Utah
2022-03-07
Recruiting
Inappropriate Sinus Tachycardia Registry
NCT05107635Inappropriate Sinus Tachycardia, Postural Tachycardia Syndrome
AtriCure, Inc.
Observational
500
California, Florida, Kansas, Maryland, Ohio, Texas, Utah, Washington
2022-03-01
Active, closed
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
NCT05222802Glioblastoma Multiforme
Katmai Pharmaceuticals Inc.
Phase 1
52
California, Florida, Massachusetts, Michigan, New York, Ohio, Tennessee, Utah
2022-02-25
Recruiting
US Post-Market Surveillance Study of the Surfacer System
NCT05050799Venous Disease
Merit Medical Systems, Inc.
Observational
30
Arizona, Florida, Georgia, Ohio, Texas, Utah, Virginia
2022-02-08
Recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479Myeloid Leukemia, Philadelphia Positive
DrugABL001
Novartis Pharmaceuticals
Phase 1/2
34
Indiana, Massachusetts, Mississippi, New York, Ohio, Pennsylvania, Texas, Utah
2021-12-27
Active, closed
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
NCT04910022Glioblastoma, Diffuse Glioma
DrugsNMS-03305293·Temozolomide
Nerviano Medical Sciences
Phase 1/2
150
Arizona, California, Florida, Massachusetts, Minnesota, New York, Texas, Utah
2021-12-01
By invitation
Multi-Center Clinical Database of Infants for the Investigation of Early Nutrition Biomarkers
NCT05049655Infant Development
ByHeart
Observational
2,000
Alabama, Arizona, Arkansas, Idaho, Ohio, South Carolina, Tennessee, Utah
2021-10-19
Active, closed
A Multi-Center Post-Market Data Collection Protocol to Evaluate the Performance of Orthofix Spine Devices
NCT05082090Spinal Disorders/Injuries
Orthofix Inc.
Observational
2,000
California, Louisiana, Mississippi, North Carolina, Rhode Island, Utah, Virginia
2021-09-15
Recruiting
Perform Humeral System Study
NCT05067543Osteoarthritis Shoulder, Avascular Necrosis, Post-traumatic Arthrosis of Other Joints, Shoulder Region, Rotator Cuff Tear Arthropathy
Stryker Trauma and Extremities
Observational
300
Kentucky, Minnesota, Missouri, Ohio, South Dakota, Utah
2021-09-12
Active, closed
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
NCT05023551High Grade Glioma, Glioblastoma Multiforme
Sumitomo Pharma America, Inc.
Phase EARLY_PHASE1
39
California, Massachusetts, Missouri, New Jersey, New York, Utah
2021-09-08
Active, closed
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
NCT04956744Multiple Sclerosis
ImStem Biotechnology
Phase 1
30
Georgia, Massachusetts, Utah
2021-08-31
Active, closed
MElanoma Research Lymph Node Prediction Implementation National_001
NCT04759781Melanoma
SkylineDx
Observational
1,820
Florida, Georgia, Kentucky, Michigan, Minnesota, New York, North Carolina, Utah
2021-08-25
Recruiting
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
NCT05004129Congenital Myotonic Dystrophy
DrugTideglusib
AMO Pharma Limited
Phase 2/3
76
Arkansas, California, Illinois, Iowa, New York, Pennsylvania, Utah, Virginia
2021-08-23
Active, closed
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
NCT04994795Non-small Cell Lung Cancer Metastatic
Sophia Genetics SAS
Observational
4,000
Iowa, Massachusetts, Minnesota, New York, Utah, Wisconsin
2021-08-21
Recruiting
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT04775745CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma
DrugRocbrutinib
Newave Pharmaceutical Inc
Phase 1
60
North Carolina, Ohio, Utah
2021-07-19
Active, closed
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
NCT04754087Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip
Zimmer Biomet
Not applicable
300
Colorado, Indiana, North Carolina, Oregon, Utah
2021-07-07
Active, closed
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
NCT04768972Amyotrophic Lateral Sclerosis
Ionis Pharmaceuticals, Inc.
Phase 3
89
California, Maryland, Massachusetts, Missouri, New York, Ohio, Utah
2021-06-14
Active, closed
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsBispecific·Tagrisso·Osimertinib
Merus B.V.
Phase 1/2
194
California, Tennessee, Utah, Virginia
2021-04-28
Active, closed
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
NCT04838444Chikungunya Virus Infection
Valneva Austria GmbH
Phase 3
363
Arizona, Florida, Illinois, Kentucky, Nebraska, Tennessee, Texas, Utah
2021-04-02
Active, closed
Beating Heart Mitral Valve Repair With the HARPOON™ System
NCT04375332Mitral Regurgitation
Edwards Lifesciences
Not applicable
25
California, Georgia, Maryland, Michigan, Minnesota, Oregon, Tennessee, Utah
2020-12-16
Active, closed
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
NCT04648202Advanced Cancer, Metastatic Cancer
invoX Pharma Limited
Phase 1
82
Connecticut, Texas, Utah
2020-11-18
Active, closed
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
NCT04577833Prostatic Neoplasms
DrugsAbiraterone acetate·Niraparib·Prednisone
Janssen Research & Development, LLC
Phase 1
136
Utah
2020-11-13
Active, closed
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
NCT04281485Duchenne Muscular Dystrophy
Pfizer
Phase 3
114
Arkansas, California, Florida, Iowa, Kansas, North Carolina, Pennsylvania, Utah
2020-11-05
Active, closed
Gene Transfer Study in Patients With Late Onset Pompe Disease
NCT04174105Pompe Disease (Late-onset)
Astellas Gene Therapies
Phase 1/2
11
California, Utah
2020-10-27
Active, closed
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
NCT04093349Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II
Spark Therapeutics, Inc.
Phase 1/2
4
Arizona, California, Georgia, Kansas, Minnesota, Oregon, Pennsylvania, Utah
2020-10-01
Active, closed
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
NCT04592653Advanced Solid Tumor
DrugsKeytruda·Pembrolizumab
Mural Oncology, Inc
Phase 1/2
78
Michigan, Texas, Utah, Virginia
2020-09-30
Active, closed
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
NCT04285086Essential Thrombocythemia
DrugsAnagrelide·Besremi
PharmaEssentia
Phase 3
174
Arizona, Missouri, Texas, Utah
2020-08-25
Active, closed
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
NCT04191304Hypereosinophilic Syndrome
DrugBenralizumab
AstraZeneca
Phase 3
134
California, Georgia, Maryland, Michigan, North Carolina, Ohio, Utah
2020-07-20
Active, closed
Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:
NCT02616484Pyruvate Dehydrogenase Complex Deficiency
Saol Therapeutics Inc
Phase 3
34
California, District of Columbia, Florida, Ohio, Pennsylvania, Texas, Utah, Washington
2020-07-14
Recruiting
Efficacy and Safety of the CG-100 Intraluminal Bypass Device
NCT04184973Rectal Cancer, Rectal Tumor, Rectal/Anal
Colospan Ltd.
Not applicable
250
California, Colorado, Michigan, Rhode Island, Utah
2020-06-23
Active, closed
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
NCT04517149X-Linked Retinitis Pigmentosa
4D Molecular Therapeutics
Phase 1/2
21
Colorado, Florida, Michigan, New York, North Carolina, Oregon, Texas, Utah
2020-06-09
Active, closed
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
NCT04483440Choroideremia
4D Molecular Therapeutics
Phase 1
13
Texas, Utah
2020-06-02
Active, closed
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
NCT03911505Pompe Disease (Late-onset)
DrugsCipaglucosidase alfa·Miglustat
Amicus Therapeutics
Phase 3
21
Florida, Georgia, Missouri, North Carolina, Ohio, Pennsylvania, Utah, Virginia
2020-02-13
Recruiting
Observational, Non-Interventional Study Supporting Validation of eVO2peak Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)
NCT05678530Cardiopulmonary
Prolaio
Observational
2,000
Arizona, California, Delaware, Florida, Illinois, Minnesota, Texas, Utah
2019-06-06
Active, closed
NOVOCART 3D Treatment Following Microfracture Failure
NCT03219307Articular Cartilage Defect
Aesculap Biologics, LLC
Phase 3
30
Illinois, Ohio, Utah
2018-11-30
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
California, Kansas, Louisiana, New Mexico, New York, South Carolina, Texas, Utah
2018-11-28
Active, closed
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
NCT03616587ER+ HER2- Advanced Breast Cancer
DrugCamizestrant
AstraZeneca
Phase 1
396
Colorado, Florida, Pennsylvania, Tennessee, Utah
2018-10-11
Active, closed
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
NCT03521154Non Small Cell Lung Cancer (Stage III)
DrugOsimertinib
AstraZeneca
Phase 3
216
California, Georgia, New Jersey, Utah, Wisconsin
2018-07-19
Active, closed
Clinical Study of Edwards Cardioband FIT Valve Repair System
NCT03382457Tricuspid Regurgitation
Edwards Lifesciences
Not applicable
75
Illinois, Minnesota, New Jersey, New York, Oregon, Pennsylvania, Texas, Utah
2018-07-01
Active, closed
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
NCT03401788VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation
DrugBelzutifan
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
50
Maryland, Massachusetts, Michigan, Pennsylvania, Tennessee, Texas, Utah
2018-05-02
Recruiting
Mucopolysaccharidosis VII Disease Monitoring Program
NCT03604835Mucopolysaccharidosis VII, MPS VII, MPS 7, Sly Syndrome
Ultragenyx Pharmaceutical Inc
Observational
50
California, District of Columbia, Illinois, Michigan, New York, Utah, Washington
2018-01-29
By invitation
Collection of Anonymized Samples
NCT03319446Healthy, Respiratory Disease, Gastrointestinal Disease
BioFire Diagnostics, LLC
Observational
1,500
Utah
2017-10-09
Active, closed
The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study
NCT02979587Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation
Medtronic Heart Valves
Not applicable
86
California, Connecticut, Minnesota, Ohio, Pennsylvania, Texas, Utah, Washington
2017-01
Active, closed
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
NCT02736656Attention-Deficit/Hyperactivity Disorder
DrugViloxazine
Supernus Pharmaceuticals, Inc.
Phase 3
1,400
Arkansas, California, Colorado, Florida, Oklahoma, Tennessee, Texas, Utah
2016-02-02
Active, closed
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
NCT02029443Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
DrugAcalabrutinib
Acerta Pharma BV
Phase 1/2
306
Massachusetts, New York, Ohio, Texas, Utah, Washington
2014-01-30
Active, closed
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722Multiple Sclerosis
DrugsAvonex·Fingolimod
Novartis Pharmaceuticals
Phase 3
240
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, Pennsylvania, Utah
2013-07-26
Active, closed
A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee
NCT01542580Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity
Zimmer Biomet
Observational
255
Illinois, Nevada, Utah, Virginia
2012-03
Rows per page Showing 1–300 of 300
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/utah

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 300 of those studies with a site in Utah.

How many clinical trials are recruiting in Utah?

171 of the 300 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 11 have not yet opened recruitment, 106 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Utah), 300 studies
PhaseStudiesRecruitingShare
Phase 1745524.7%
Phase 1/2603420%
Phase 3472415.7%
Not applicable411513.7%
Observational372112.3%
Phase 228169.3%
Phase 2/3732.3%
Phase 4421.3%
Phase EARLY_PHASE1210.7%

Most active sponsors

Lead sponsors with the most studies (Utah)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals1310
Eli Lilly and Company99
GlaxoSmithKline64
Merck Sharp & Dohme LLC53
Pfizer53
Sanofi53
Alcon Research43
AstraZeneca41
Bristol-Myers Squibb43
dōTERRA International40
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.